ArticleFrontiers in aging neuroscience2026
Clinical heterogeneity of Pisa syndrome across Lewy body disorders: a multicenter comparison of Parkinson's disease and dementia with Lewy bodies.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pisa syndrome (PS) is well recognized in Parkinson's disease (PD) but has been less studied in dementia with Lewy bodies (DLB), and direct comparisons are scarce. The aim of this study is to compare the clinical expression of PS across PD and DLB. Methods: In this multicenter cross-sectional study, patients were classified as PD without PS ( Results: In both disorders, PS was associated with longer disease duration, worse daily functioning, and more recurrent falls. Significant disease × PS interactions were observed across cognitive, neuropsychiatric, gait, and fall outcomes. DLB-PS carried the heaviest cognitive and neuropsychiatric burden, whereas PD-PS showed the greatest motor and gait impairment. In PD, PS was independently associated with disease duration, MDS-UPDRS-III score, gait symmetry, and stride length. In DLB, PS was independently associated with lower attention and visuospatial/executive scores, greater hallucination severity, and a higher CDR stage. Attention/visuospatial dysfunction partly mediated the association between PS and recurrent falls in DLB, whereas gait asymmetry/stride impairment partly mediated the same association in PD. Conclusion: PS is not a uniform phenotype across Lewy body disorders. Our findings suggest that it behaves relatively more like a cognition-neuropsychiatry-associated axial syndrome in DLB, whereas in PD, it shows stronger associations with motor and gait features. The effect sizes are modest, indicating that PS is a multifactorial clinical sign rather than a strong predictor of any single domain.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.